SCHEMBL26086348

SCHEMBL26086348

COCCOc1ccc([N+](=O)[O-])c(F)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
PTGES O14684 1/20 0.49
TDP1 Q9NUW8 2/20 0.49
ATM Q13315 1/20 0.49
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
HPGD P15428 1/20 0.44
MEN1 O00255 2/20 0.44
MAPK1 P28482 1/20 0.44
RECQL P46063 1/20 0.44
RAPGEF3 O95398 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HTT P42858 1/20 0.40
ALPG P10696 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14334509 0.88 PTGES (0.49) MAPTPTGESTDP1KMT2ASMN1; SMN2
SCHEMBL564684 0.86 ATM (0.50) MAPTPTGESTDP1ATMKMT2A
SCHEMBL4014456 0.86 MAPT (0.68) MAPTPTGESTDP1ATMKMT2A
SCHEMBL12210768 0.86 MAPT (0.60) MAPTPTGESTDP1ATMKMT2A
SCHEMBL1663359 0.86 MAPT (0.55) MAPTTDP1KMT2ASMN1; SMN2NPC1
SCHEMBL891173 0.84 MAPT (0.48) MAPTPTGESTDP1ATMKMT2A
SCHEMBL2338671 0.83 TDP1 (0.50) MAPTPTGESTDP1ATMKMT2A
SCHEMBL16025774 0.83 MAPT (0.64) MAPTKMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL607025 0.83 MAPT (0.67) MAPTTDP1ATMKMT2ASMN1; SMN2
SCHEMBL1962346 0.82 CHRNB2 (0.58) MAPTTDP1ATMALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026722-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Université Côte d’Azur (FR) 2025-01-23 US disclosed
EP-4399202-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2024-07-17 EP disclosed
WO-2023072962-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2023-05-04 WO disclosed
EP-4169904-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS Yukin Therapeutics (FR) 2023-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026722-A1 SUBSTITUTED QUINOLINES AS IMPROVED NF-KB-INDUCING KINASE (NIK) INHIBITORS NFKBIA, IKBKG, IKBKB MAPT 2509/4885PTGES 1107/4885TDP1 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.